Drug intelligence / Profile preview

CircFam53B-219aa

Development stage: Phase 1
Modality: Peptides
Administration: Intramuscular, Dendritic Cell Vaccine Administration

Overview

CircFam53B-219aa is a cryptic peptide encoded by circular RNA (CircFAM53B). This peptide is specifically highly expressed in breast cancer tissues and has demonstrated the ability to activate antigen-specific T cell immune responses. In preclinical studies, when CircFAM53B-219aa is loaded into dendritic cells (DC), the resulting vaccine has shown significant inhibition of tumor growth in animal models with high CircFAM53B expression. It is being investigated as a monotherapy and in combination with camrelizumab for the treatment of HER2-negative advanced breast cancer.

Targets

CD8A (CD8 alpha/beta Coreceptor)MHC II (Major histocompatibility complex class II receptor)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)

Beyond the preview

Go deeper on CircFam53B-219aa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CircFam53B-219aa.

Explore the full profile